Holen Sie sich die Stockscreener-App
23.42
0.30%
-0.07
Handel nachbörslich:
23.79
0.37
+1.58%
Schlusskurs vom Vortag:
$23.49
Offen:
$23.72
24-Stunden-Volumen:
850.23K
Relative Volume:
0.68
Marktkapitalisierung:
$2.93B
Einnahmen:
$376.07M
Nettoeinkommen (Verlust:
$-16.14M
KGV:
-167.41
EPS:
-0.1399
Netto-Cashflow:
$-16.31M
1W Leistung:
+0.56%
1M Leistung:
-0.89%
6M Leistung:
-3.94%
1J Leistung:
+51.98%
1-Tages-Spanne:
$23.15
$24.03
1-Wochen-Bereich:
$22.13
$24.03
52-Wochen-Spanne:
$12.42
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
23.42 | 2.94B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis director Howard Welgus sells $164,219 in company stock - Investing.com
Arcutis Biotherapeutics (ARQT) director sells 7,144 shares under 10b5-1 plan - Stock Titan
Director sale: Arcutis Biotherapeutics (NASDAQ: ARQT) plans to sell 684 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch - Stock Titan
3,172-Share Form 144 Filed by Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) reports vesting and insider sales in Form 144 - Stock Titan
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Kornitzer Capital Management Inc. KS Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates - Stock Titan
Will Arcutis Biotherapeutics, Inc. (ARQT) report negative earnings next week? What you should know - MSN
Jennison Associates LLC Has $196.25 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys 147,586 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Calamos Advisors LLC Takes $1.57 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis submits application to expand Zoryve use to infants - Investing.com UK
Arcutis Biotherapeutics (ARQT) Expands Zoryve Cream Application for Infants - GuruFocus
Arcutis submits sNDA for roflumilast cream 0.05% in atopic dermatitis for infants down to 3 months - Contemporary Pediatrics
Arcutis submits application to expand Zoryve use to infants By Investing.com - Investing.com South Africa
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - The Manila Times
FDA filing targets eczema treatment for babies as young as 3 months - Stock Titan
ARQT Stock Price, Quote & Chart | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Q4 2025 Arcutis Biotherapeutics Inc Earnings Call Transcript - GuruFocus
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves - Yahoo Finance
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target - Yahoo Finance
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN) - The Globe and Mail
ARQT (Arcutis Biotherapeutics Inc.) tops Q4 2025 EPS estimates on 91 percent year over year revenue growth, shares slip 2.03 percent.Crowd Risk Alerts - Xã Thanh Hà
Is Arcutis (ARQT) stock building trend strength (Investor Interest) 2026-04-22Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - The Manila Times
AAD backs steroid-free ZORYVE for children with eczema - Stock Titan
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
[ARS] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) 2026 proxy details votes on board, pay and auditor - Stock Titan
Is Arcutis (ARQT) stock losing support (Slight Loss) 2026-04-20Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants - Insider Monkey
5 Overlooked Growth Stocks to Buy Now - Insider Monkey
Phocas Financial Corp. Trims Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Tudor Investment Corp ET AL Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AMI Asset Management Corp Sells 46,829 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):